NCCN Guidelines, National Comprehensive Cancer Network

National Comprehensive Cancer Network® (NCCN®) Recommends as an NCCN Category 2A Treatment Option2

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) include afamitresgene autoleucel as a treatment option for patients with advanced/metastatic synovial sarcoma who have received prior therapy, are positive for HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P, and whose tumor expresses the MAGE-A4 antigen.

Illustrated icon of a test tube, microscope slide plate, and checklist
Are your patients eligible for TECELRA?
Explore eligibility requirements to see if you have patients in your practice for whom TECELRA may be an option, and learn about the specific biomarker tests needed to confirm if your patients may be prescribed treatment.
Illustrated icon of a journey between two location pins
What is the TECELRA treatment process?
Over a period of ~6 weeks, your patients’ T cells will be collected, engineered, and delivered back to the predetermined Authorized Treatment Center (ATC) for infusion.1 Dive into the process to discover how TECELRA is made.
Illustrated icon of a document in a folder
Resources for your practice and patients
Find helpful information for your practice, including how to order TECELRA, as well as materials to guide your patients through their treatment journey.
Have
questions?
Connect with a Cell Therapy Navigator at 1-855-24MYADAP (855-246-9232) 1-855-24MYADAP (855-246-9232) or adaptimmuneassist@​adaptimmune.com
ATC=Authorized Treatment Center; HLA=human leukocyte antigen; MAGE=melanoma-associated antigen; NCCN=National Comprehensive Cancer Network; SyS=synovial sarcoma; TCR=T-cell receptor.
Image of an engineered mechanical yellow and magenta butterfly on a purple flower in a field